Foreløpig undersøkelse over virkningen på nitratinnholdet i grønnsaker ved bruk av ulike gjødselslag ved stigende menge N

Fra institutt for grønnsaksdyrking. Stensiltrykk nr. 66.Nitratinnhold i grønnsaker er et aktuelt spørsmål for konservindustrien. I 1973 gjennomførte en ved Norges landbrukshøgskole en preliminær undersøkelse.med henblikk på å studere virkningen av ulike mengder N gitt i form av ammoniumsulfat, kalksalpeter og urea. Nitratanalyse ble utført på kinakål og grønnkål. Mengdene som ble gitt av de ulike gjødselslag tilsvarte O, 3,1, 6,2 og 12,4 kg N pr. daa i form av overgjødsling. Den største mengde tilsvarte 80 kg kalksalpeter pr. daa. Forsøket ble sådd i 31. uke. Overgjødsling fant sted i 36. uke, og høsting og analyser ble foretatt 40.-41. uke. Resultatene viser at det var stigning i nitratinnholdet med Økende mengder N. Det var liten forskjell mellom virkningene av de ulike gjødselslagene ved samme N-konsentrasjon, likevel en tendens til at ammoniumsulfat ga noe mindre nitratinnhold enn kalksalpeter som ga den mest markerte økningen

Foreløpig undersøkelse over virkningen på nitratinnholdet i grønnsaker ved bruk av ulike gjødselslag ved stigende menge N

Fra institutt for grønnsaksdyrking. Stensiltrykk nr. 66.Nitratinnhold i grønnsaker er et aktuelt spørsmål for konservindustrien. I 1973 gjennomførte en ved Norges landbrukshøgskole en preliminær undersøkelse.med henblikk på å studere virkningen av ulike mengder N gitt i form av ammoniumsulfat, kalksalpeter og urea. Nitratanalyse ble utført på kinakål og grønnkål. Mengdene som ble gitt av de ulike gjødselslag tilsvarte O, 3,1, 6,2 og 12,4 kg N pr. daa i form av overgjødsling. Den største mengde tilsvarte 80 kg kalksalpeter pr. daa. Forsøket ble sådd i 31. uke. Overgjødsling fant sted i 36. uke, og høsting og analyser ble foretatt 40.-41. uke. Resultatene viser at det var stigning i nitratinnholdet med Økende mengder N. Det var liten forskjell mellom virkningene av de ulike gjødselslagene ved samme N-konsentrasjon, likevel en tendens til at ammoniumsulfat ga noe mindre nitratinnhold enn kalksalpeter som ga den mest markerte økningen

Forsøk i gang ved Institutt for grønnsakdyrking 1974 1975

Forsøk i gang ved Institutt for grønnsakdyrking 1974. Forsøk i gang ved Institutt for grønnsakdyrking 1975, arbeidet består av flere forfattere

Forsøk i gang ved Institutt for grønnsakdyrking 1974 1975

Forsøk i gang ved Institutt for grønnsakdyrking 1974. Forsøk i gang ved Institutt for grønnsakdyrking 1975, arbeidet består av flere forfattere

Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19

Importance: Research diversity and representativeness are paramount in building trust, generating valid biomedical knowledge, and possibly in implementing clinical guidelines. Objectives: To compare variations over time and across World Health Organization (WHO) geographic regions of corticosteroid use for treatment of severe COVID-19; secondary objectives were to evaluate the association between the timing of publication of the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial (June 2020) and the WHO guidelines for corticosteroids (September 2020) and the temporal trends observed in corticosteroid use by region and to describe the geographic distribution of the recruitment in clinical trials that informed the WHO recommendation. Design, setting, and participants: This prospective cohort study of 434 851 patients was conducted between January 31, 2020, and September 2, 2022, in 63 countries worldwide. The data were collected under the auspices of the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC)-WHO Clinical Characterisation Protocol for Severe Emerging Infections. Analyses were restricted to patients hospitalized for severe COVID-19 (a subset of the ISARIC data set). Exposure: Corticosteroid use as reported to the ISARIC-WHO Clinical Characterisation Protocol for Severe Emerging Infections. Main outcomes and measures: Number and percentage of patients hospitalized with severe COVID-19 who received corticosteroids by time period and by WHO geographic region. Results: Among 434 851 patients with confirmed severe or critical COVID-19 for whom receipt of corticosteroids could be ascertained (median [IQR] age, 61.0 [48.0-74.0] years; 53.0% male), 174 307 (40.1%) received corticosteroids during the study period. Of the participants in clinical trials that informed the guideline, 91.6% were recruited from the United Kingdom. In all regions, corticosteroid use for severe COVID-19 increased, but this increase corresponded to the timing of the RECOVERY trial (time-interruption coefficient 1.0 [95% CI, 0.9-1.2]) and WHO guideline (time-interruption coefficient 1.9 [95% CI, 1.7-2.0]) publications only in Europe. At the end of the study period, corticosteroid use for treatment of severe COVID-19 was highest in the Americas (5421 of 6095 [88.9%]; 95% CI, 87.7-90.2) and lowest in Africa (31 588 of 185 191 [17.1%]; 95% CI, 16.8-17.3). Conclusions and relevance: The results of this cohort study showed that implementation of the guidelines for use of corticosteroids in the treatment of severe COVID-19 varied geographically. Uptake of corticosteroid treatment was lower in regions with limited clinical trial involvement. Improving research diversity and representativeness may facilitate timely knowledge uptake and guideline implementation

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing comorbidities, vital signs, chronic and acute treatments, complications, dates of hospitalization and discharge, mortality, viral strains, vaccination status, and other data. Here, we present the dataset characteristics, explain its architecture and how to gain access, and provide tools to facilitate its use

Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms

Background: COVID-19 is primarily known as a respiratory illness; however, many patients present to hospital without respiratory symptoms. The association between non-respiratory presentations of COVID-19 and outcomes remains unclear. We investigated risk factors and clinical outcomes in patients with no respiratory symptoms (NRS) and respiratory symptoms (RS) at hospital admission. Methods: This study describes clinical features, physiological parameters, and outcomes of hospitalised COVID-19 patients, stratified by the presence or absence of respiratory symptoms at hospital admission. RS patients had one or more of: cough, shortness of breath, sore throat, runny nose or wheezing; while NRS patients did not. Results: Of 178,640 patients in the study, 86.4 % presented with RS, while 13.6 % had NRS. NRS patients were older (median age: NRS: 74 vs RS: 65) and less likely to be admitted to the ICU (NRS: 36.7 % vs RS: 37.5 %). NRS patients had a higher crude in-hospital case-fatality ratio (NRS 41.1 % vs. RS 32.0 %), but a lower risk of death after adjusting for confounders (HR 0.88 [0.83-0.93]). Conclusion: Approximately one in seven COVID-19 patients presented at hospital admission without respiratory symptoms. These patients were older, had lower ICU admission rates, and had a lower risk of in-hospital mortality after adjusting for confounders